ArticleDiscover oncology2026
Diagnostic potential of serum humanin in breast cancer among the Egyptian population.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobally, breast cancer is the most frequently diagnosed malignancy and the second leading cause of cancer-related mortality among women. The ongoing pursuit of early detection has driven interest in identifying and validating novel diagnostic biomarkers that could enhance prognosis and therapeutic outcomes. Humanin, a mitochondrial-derived peptide (MDP) with reported cytoprotective properties, has been implicated in cancer biology and may play a role in breast cancer pathogenesis.
methodsA total of 75 female patients with primary non-metastatic breast cancer and 70 age-matched healthy controls of comparable age were enrolled in this study. Serum concentrations of humanin were quantified using an enzyme-linked immunosorbent assay (ELISA).
resultsSerum humanin concentrations were significantly elevated in breast cancer patients compared with healthy controls (p < 0.001). Receiver operating characteristic (ROC) curve analysis demonstrated that humanin effectively differentiated breast cancer patients from controls, with a sensitivity of 78.7% and specificity of 62.9%.
conclusionThese findings suggest that humanin could serve as a promising biomarker for breast cancer screening and early detection. Further large-scale studies are warranted to validate its diagnostic potential and establish its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.